Jim Jinn-Chyuan Sheu
Affilation: China Medical University Hospital, Taiwan
Journal Associated: Journal of Genetic Medicine and Gene Therapy
Jim Jinn-Chyuan Sheu, male, molecular biologist, graduated from Department of Life Science, National Tsing-Hua University in 2002. Currently, Dr. Sheu is studying genetic alterations of novel oncogenes in oral and bladder cancers at National Sun Yatsen University, Taiwan as a full professor. Based on comparative analyses between genomic and transcriptome maps, Dr. Sheu has successfully validated EGFR activation, either through gene amplification/overexpression or activation of down stream targets, is the most frequent genetic event in oral cancer. On the other hand, he recently found LRIG1, a negative regulator for EGFR signaling, as a tumor suppressor in head and neck cancer through down-regulation of EGFR ligands and extracellular remodeling activity. Previously, Dr. Sheu served as a faculty at China Medical University (CMU) as well as a Research Scientist at China Medical University Hospital (CMUH), Taiwan. Therefore, Dr. Sheu also investigated molecular mechanisms of effective Chinese herbs/treatments for cancer. The association of a chromatin remodeling factor, Rsf-1/HBXAP, in cancer was discovered when Dr. Sheu studied at the Johns Hopkins Medical Institutions as a Research Fellow during 2004 to 2006. In recent years, Dr. Sheu continued his study to verify the molecular mechanisms of Rsf-1 involved in cancer development and progression. When Dr. Sheu was in Tsing Hua as a PhD student, he studied on developing effective therapeutics against oncogenic markers/proteins for B cell lymphoma. Significantly, Dr. Sheu identified a functional domain in Igα molecule, a neoplastic marker for B cell lymphoma which can trigger cell going into apoptosis, by employing computational protein structure modeling, and later on proved by experiments. Before he came to Hopkins, Dr. Sheu served as Director of Protein Drugs and Project Leader at Development Center for Biotechnology, Taiwan to develop key technologies for structure-based high-through protein drug screening. With the working experiences at both academic and industrial organizations, Dr. Sheu therefore holds the key skills and knowledge to explore other oncogenic proteins in different cancer types.
Cancer genetics and genomics, epigenetics, chromatin remodeling, signal transduction profiling, new drug discovery & development, complementary & alternative medicine, antibody/vaccine engineering.